Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
grade D 23.19 -1.74% -0.41
MGNX closed down 1.74 percent on Tuesday, October 20, 2020, on 62 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Nov 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical MGNX trend table...

Date Alert Name Type % Chg
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness -1.74%
Below Lower BB Weakness -1.74%
Down 3 Days in a Row Weakness -1.74%
Down 4 Days in a Row Weakness -1.74%
Older End-of-Day Gignals for MGNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 17 hours ago
Down 1% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Rose Above Lower Bollinger Band about 18 hours ago
Up 1% about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Treatment Of Cancer Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Antibody Technology Platforms Novel Cancer

Is MGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.18
52 Week Low 4.04
Average Volume 507,420
200-Day Moving Average 18.62
50-Day Moving Average 26.42
20-Day Moving Average 25.09
10-Day Moving Average 24.94
Average True Range 1.40
ADX 19.26
+DI 12.72
-DI 28.90
Chandelier Exit (Long, 3 ATRs ) 26.36
Chandelier Exit (Short, 3 ATRs ) 27.22
Upper Bollinger Band 26.63
Lower Bollinger Band 23.54
Percent B (%b) -0.11
BandWidth 12.32
MACD Line -0.73
MACD Signal Line -0.53
MACD Histogram -0.1993
Fundamentals Value
Market Cap 1.25 Billion
Num Shares 54.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -6.68
Price-to-Sales 16.28
Price-to-Book 5.62
PEG Ratio 0.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.65
Resistance 3 (R3) 24.75 24.38 24.40
Resistance 2 (R2) 24.38 24.01 24.32 24.32
Resistance 1 (R1) 23.78 23.78 23.60 23.68 24.24
Pivot Point 23.41 23.41 23.31 23.35 23.41
Support 1 (S1) 22.81 23.04 22.63 22.71 22.14
Support 2 (S2) 22.44 22.81 22.38 22.06
Support 3 (S3) 21.84 22.44 21.98
Support 4 (S4) 21.74